Archived Press Releases
September 14, 2005 Onyvax Granted Broad European Patent For Prostate Cancer Vaccines
June 17, 2005 Onyvax Publishes Results Of Phase II Prostate Cancer Vaccine Showing Significant Steps Towards Delaying Disease Progression
May 16, 2005 Onyvax-P May Significantly Extend Progression Free Survival of Metastatic Prostate Cancer Patients
April 19, 2005 Onyvax-105 Cancer Vaccine Shows Encouraging Clinical Results in Osteosarcoma Patients After Intensive Chemotherapy
February 23, 2005 Onyvax Announces EC Grant For Cancer Vaccine Research Collaboration
February 21, 2005 Onyvax US Clinical Advisory Board Reviews Phase II Data And Gives Input To Onyvax-P Late-Stage Clinical Trial Design In Prostate Cancer
February 15, 2005 Onyvax appoints Richard de Souza as Non Executive Director
November 17, 2004 Onyvax Discovers Clinical Responses To Prostate Cancer Vaccine Correlate With Immunological Data Analysis
October 29, 2004 Onyvax Announces EC Funded Research Collaboration To Develop New Lung Cancer Treatments
June 17, 2004 Final Phase II Data Shows That Onyvax-P May Significantly Extend Progression Free Survival For Men With Advanced Prostate Cancer
March 29, 2004 Onyvax and University of Michigan Develop PSA Expressing Cell Lines For Prostate Cancer Vaccine Research
March 3, 2004 Onyvax Issued Broad US Patent For Prostate Cancer Vaccines
February 23, 2004 Onyvax Appoints Dr John Brown As Non Executive Director
January 15, 2004 Onyvax and The Mayo Clinic to Develop Cancer Vaccines for Ovarian Cancer
December 10, 2003 Scancell, Onyvax and CRT Announce Agreement to Facilitate the Development of “Immunobody” Cancer Vaccine Technology
September 24, 2003 Berna Biotech and Onyvax announce collaboration
July 3, 2003 Onyvax Presents Interim Phase II Data on its Prostate Cancer Vaccine at the British Cancer Research Meeting
May 6, 2003 Onyvax Presents Preliminary Phase II Data on its Prostate Cancer Vaccine at American Association of Immunologists Annual Meeting
April 14, 2003 Onyvax Completes Enrolment in Phase II Prostate Cancer Clinical Trial
October 14, 2002 Onyvax Appoints J. Barrie Ward as Chairman
October 8, 2002 UK and US Companies Link to Accelerate Prostate Cancer Research
May 30, 2002 Phase II Prostate Cancer Vaccine Trial Set to Expand
January 9, 2002 Phase II Prostate Cancer Vaccine Trial Initiated
November 16, 2000 Onyvax Raises Euro17.5m To Fund Cancer Vaccine Programs
May 24, 2000 Grant of Key Cancer Vaccine Patent in US
May 2, 2000 Initiation of Clinical Trials of Onyvax Colorectal Cancer Vaccines
December 13, 1999 Onyvax Limited, Cancer Research Campaign Technology, Institute of Cancer Research and the Royal Marsden Hospital Announce Initiative in Prostate Cancer Research
June 28, 1999 Erasmus University Rotterdam and Onyvax Announce Collaboration in Prostate Cancer Research
May 11, 1999 Cancer Vaccine Licence from CRCT
March 24, 1999 Award of DTI LINK Grant
February 1999 Vaccine Trial for Prostate Cancer
March 18, 1998 Stanford Rook and Onyvax Collaboration
December 18, 1997 Onyvax Receives Venture Financing
